Target-based and phenotype-based methods are the two main approaches for drug screening.Target-based drug screening focuses on specific targets CPA highly correlated with disease mechanisms,by detecting protein-ligand...Target-based and phenotype-based methods are the two main approaches for drug screening.Target-based drug screening focuses on specific targets CPA highly correlated with disease mechanisms,by detecting protein-ligand binding structure,dynamics and affinity.Currently,the four mainstream drug targets are G protein-coupled receptors(GPCRs),kinases,ion channels,and nuclear receptors,accounting for over 70%of effective drug targets,most of which are membrane proteins and enzymes.In recent years,various new drug targets have been continuously discovered,and the research focus has shifted from simple affinity analysis to high-throughput and high-content screening,as well as exploring drug-target interaction modes.These deepen reliance on the analytical techniques to have higher sensitivity,recognition specificity,and applicability to diversified target structures,which promoting the rapid development of novel screening methods.展开更多
Objective To evaluate the safety and efficacy of mitoxantrone liposome(MIT-LIP)combined chemotherapy in treating mixed phenotype acute leukemia(MPAL).Methods December 2021 to November 2024,MPAL patients who underwent ...Objective To evaluate the safety and efficacy of mitoxantrone liposome(MIT-LIP)combined chemotherapy in treating mixed phenotype acute leukemia(MPAL).Methods December 2021 to November 2024,MPAL patients who underwent the MAED(MIT-LIP+cytarabine+etoposide+dexamethasone)regimen were retrospectively analyzed.Data on clinical characteristics,adverse reactions,therapeutic outcomes,and long-term prognoses were collected.Results A total of 7 MPAL patients who received MAED regimen were admitted.Among them,two patients were initially diagnosed with T-ALL or BALL,respectively,and transformed into AML after treatment.Three patients were initially diagnosed as MPAL(B/myeloid),one as MPAL(T/myeloid),and one with MPAL(myeloid/plasmacytoid dendritic cell).Among the 7 patients,there were 3 males and 4 females,1 chromosome abnormalities and 6 gene abnormalities,including 1 case with BCR::ABL fusion gene.The median age was 38 years(range:16-58 years).There was no clear related drug allergy and organ toxicity during MAED regimen,and the main adverse effect was hematological toxicity.After induced chemotherapy,all patientsachieved complete remission(CR),2 maintained MRD-negative CR and 1 maintained MRDpositive CR.The other 4 patients underwent allogeneic hematopoietic stem cell transplantation,2 maintained MRD-negative CR,and 2 relapsed.The current median follow-up time was 12 months,the overall survival(OS)rate was 100%,the relapse-free survival(RFS)rate was 60%,and the median OS time and median RFS time were not reached.Conclusion The MAEDDregimen demonstrates high safety and a favorable CR rate in MPAL treatment.展开更多
文摘Target-based and phenotype-based methods are the two main approaches for drug screening.Target-based drug screening focuses on specific targets CPA highly correlated with disease mechanisms,by detecting protein-ligand binding structure,dynamics and affinity.Currently,the four mainstream drug targets are G protein-coupled receptors(GPCRs),kinases,ion channels,and nuclear receptors,accounting for over 70%of effective drug targets,most of which are membrane proteins and enzymes.In recent years,various new drug targets have been continuously discovered,and the research focus has shifted from simple affinity analysis to high-throughput and high-content screening,as well as exploring drug-target interaction modes.These deepen reliance on the analytical techniques to have higher sensitivity,recognition specificity,and applicability to diversified target structures,which promoting the rapid development of novel screening methods.
文摘Objective To evaluate the safety and efficacy of mitoxantrone liposome(MIT-LIP)combined chemotherapy in treating mixed phenotype acute leukemia(MPAL).Methods December 2021 to November 2024,MPAL patients who underwent the MAED(MIT-LIP+cytarabine+etoposide+dexamethasone)regimen were retrospectively analyzed.Data on clinical characteristics,adverse reactions,therapeutic outcomes,and long-term prognoses were collected.Results A total of 7 MPAL patients who received MAED regimen were admitted.Among them,two patients were initially diagnosed with T-ALL or BALL,respectively,and transformed into AML after treatment.Three patients were initially diagnosed as MPAL(B/myeloid),one as MPAL(T/myeloid),and one with MPAL(myeloid/plasmacytoid dendritic cell).Among the 7 patients,there were 3 males and 4 females,1 chromosome abnormalities and 6 gene abnormalities,including 1 case with BCR::ABL fusion gene.The median age was 38 years(range:16-58 years).There was no clear related drug allergy and organ toxicity during MAED regimen,and the main adverse effect was hematological toxicity.After induced chemotherapy,all patientsachieved complete remission(CR),2 maintained MRD-negative CR and 1 maintained MRDpositive CR.The other 4 patients underwent allogeneic hematopoietic stem cell transplantation,2 maintained MRD-negative CR,and 2 relapsed.The current median follow-up time was 12 months,the overall survival(OS)rate was 100%,the relapse-free survival(RFS)rate was 60%,and the median OS time and median RFS time were not reached.Conclusion The MAEDDregimen demonstrates high safety and a favorable CR rate in MPAL treatment.
